<DOC>
	<DOC>NCT02673567</DOC>
	<brief_summary>This is a single center, randomized, double-blind, placebo-controlled study to assess the pharmacokinetics, safety, and tolerability of subcutaneous administration of TEV-48125 (single ascending doses and single doses up to 900 mg) in Japanese and Caucasian healthy subjects.</brief_summary>
	<brief_title>To Assess Pharmacokinetics, Safety and Tolerability of TEV-48125 in Japanese and Caucasian Healthy Subjects After a Single Subcutaneous (SC) Administration of TEV-48125</brief_title>
	<detailed_description />
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>Immunoglobulins</mesh_term>
	<mesh_term>Antibodies, Monoclonal</mesh_term>
	<criteria>The subject is a man or woman, 18 to 55 years of age, inclusive The subject has a body mass index (BMI) ranging from 17.5 to 28.0 kg/m2, inclusive The subjects must be in a good health at screening and checkin Additional inclusion criteria for Japanese subjects: Subject must be a nonnaturalized Japanese citizen and hold a Japanese passport Subject must have/had 2 Japanese parents and 4 Japanese grandparents who are all non naturalized Japanese citizens Subject has been living outside of Japan for no more than 10 years Additional inclusion criteria for Caucasian subjects: The subject has/had 2 Caucasian parents and 4 Caucasian grandparents. Caucasian includes White and Hispanic ethnicities. Additional criteria apply, please contact the investigator for more information The subject is a woman who is pregnant or lactating The subject is suffering from, or has a clinically significant history of, 1 or more of the following: cardiovascular, respiratory, hepatic, renal, gastrointestinal, endocrine, neurological, immunological, hematologic or psychiatric disorder(s) The subject has a known allergy or sensitivity to injected proteins, including monoclonal antibodies, or any other component of the formulation. In addition, presence of history of allergies requiring acute or chronic treatment Precipitation in another clinical study of a new investigational drug within 30 days (90 days for biologics) before dosing Additional criteria apply, please contact the investigator for more information</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>